Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

The aim of the study was to assess the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with non-functioning neuroendocrine pancreatic tumours (NFPNTs) and to compare survival rates in patients with NFPNTs and in patients with other neuroendocrine tumours (NETs) treated usin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nuclear medicine review. Central & Eastern Europe 2011-01, Vol.14 (2), p.73-78
Hauptverfasser:	Sowa-Staszczak, Anna, Pach, Dorota, Stefańska, Agnieszka, Tomaszuk, Monika, Lenda-Tracz, Wioletta, Mikołajczak, Renata, Pawlak, Dariusz, Chrzan, Robert, Gilis-Januszewska, Aleksandra, Przybylik-Mazurek, Elwira, Hubalewska-Dydejczyk, Alicja
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Female Humans Male Middle Aged Neuroendocrine Tumors - radiotherapy Octreotide - analogs & derivatives Octreotide - therapeutic use Organometallic Compounds - therapeutic use Pancreatic cancer Pancreatic Neoplasms - mortality Pancreatic Neoplasms - radiotherapy Peptides Radiation therapy Receptors, Peptide - therapeutic use Receptors, Somatostatin - metabolism Survival Rate Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!